The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

Table 1 Characteristics and VEGFR-1 expression of GBMs from which tissue specimens were derived

GBM patient	Tumor location	Primary (P) Recurrent (R)	Overall Survival (months)	VEGFR-1^a
1	NA	P	13	+++
2	Temporal	P	19	+
3	Temporal	P	60	−
4	Frontal	R	NA^b	++
5	Frontal	P	7	+++
6	NA	P	NA	+++
7	Frontal	P	15	+++
8	Frontal	P	2	+++
9	Temporal	P	4	+++
10	Occipital	P	33	+
11	Temporal	P	14	−
12	NA	P	NA	+
13	NA	R	NA	+
14	Temporal	P	53	+
15	Parietal	P	53	+
16	NA	P	9	+++
17	Frontal	P	NA	+
18	Frontal	P	NA	+++
19	Tempo-Parietal	R	53	+++
20	Temporal	P	NA	+++
21	NA	P	NA	+++
22	Temporal	P	NA	+
23	Parietal	P	6	+++
24	NA	P	NA	++
25	Temporal	P	NA	+++
26	NA	R	NA	+
27	Frontal	R	NA	+
28	Occipital	P	NA	+++
29	NA	P	NA	+++
30	Temporal	P	NA	+++
31	NA	P	NA	++
32	Temporal	P	NA	+++
33	Temporal	P	6	+
34	NA	P	NA	+++
35	Frontal	P	12	+
36	Fronto-Temporal	P	NA	++
37	Occipital	P	8	+++
38	Frontal	P	NA	−/+
39	Temporal	P	NA	+++
40	NA	P	38	−/+
41	NA	R	24	++
42	Frontal	P	12	+

^aThe number of positive VEGFR-1 cells in the tumor mass was counted in a total of 50 cells.VEGFR-1 staining was scored as percentage of positively stained cells: -, <10%; −/+, 11–25%; +, 26–50%; ++, 51–75%; +++, >75%
^bNA: not available

ISSN: 1756-9966